Cell therapy with lentiviral transduced CSF2RA transgene in the treatment of hereditary pulmonary alveolar proteinosis

US12043844B2 · kind B2 · utility

Assignees

• Children's Hospital Medical Center · US
• MEDIZINISCHE HOCHSCHULE HANNOVER · DE

Inventors

• Bruce C. Trapnell · Monroe, US
• Takuji Suzuki · Yokohama, JP
• Thomas Moritz · Berlin, DE
• Nico Lachmann · Burgdorf, DE
• Axel Schambach · Seevetal, DE

Key dates

• Filing date: May 16, 2018
• Grant date: Jul 23, 2024
• Expiry date: Sep 17, 2041

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2830/008
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The disclosure provides compositions and methods for cell therapy of hPAP in humans using gene corrected and in vitro differentiated patient autologous macrophage cells. The disclosure also provides compositions in the form of a cell product and related compositions and methods for making the cell product and for direct pulmonary transplantation of same.